Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland Identifier:
First received: April 24, 2007
Last updated: March 8, 2012
Last verified: March 2012
The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma triglyceride concentrations and improves hepatic glucose metabolism in patients with the metabolic syndrome, Familial Hypertriglyceridemia and Familial Combined Hyperlipidemia.

Condition Intervention Phase
Metabolic Syndrome
Familial Hypertriglyceridemia
Familial Combined Hyperlipidemia
Drug: chenodeoxycholic acid
Drug: placebo capsules
Early Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Activation of the Farnesoid X Receptor (FXR) on Hepatic Lipid and Glucose Metabolism in Patients With the Metabolic Syndrome and Familial Forms of Hypertriglyceridemia

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • plasma triglyceride concentrations [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • hepatic insulin sensitivity [ Time Frame: 3 months ]
  • heptic triglyceride content [ Time Frame: 3 months ]

Enrollment: 30
Study Start Date: October 2004
Arms Assigned Interventions
Active Comparator: A
chenodeoxycholic acid treatment
Drug: chenodeoxycholic acid
chenodeoxycholic acid 500 mg capsules tid po
Placebo Comparator: B
placebo treatment
Drug: placebo capsules
placebo capsules containing mannitol tid po

Detailed Description:

Insulin resistance has been found to be the key pathophysiological factor of the metabolic syndrome and may precede the onset of impaired glucose tolerance, diabetes and dyslipidemia. Recently, nonalcoholic fatty liver disease (NAFLD), has been identified as another feature of this syndrome. Importantly, a close relation between liver fat content and hepatic insulin sensitivity has been described. We hypothesize that activation of FXR with chenodeoxycholic acid decreases hepatic de novo lipogenesis and subsequently hepatic fat content and triglyceride production. The decrease in liver fat content will be associated with improved hepatic insulin sensitivity and a decrease in hepatic glucose production.

Patients diagnosed with metabolic syndrome, familial hypertriglyceridemia or familial combined hyperlipidemia will be recruited from the the outpatients department of the Division of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Basel. Eligible patients will be admitted to the CRC for metabolic studies, including baseline blood samples for the measurement of hormones, cytokines and adipokines, euglycemic-hyperinsulinemic clamp studies for the assessment of glucose turnover and insulin sensitivity and in vivo NMR studies to determine intrahepatic and intramyocellular lipid content. Patients will alternatively receive chenodeoxycholic acid and placebo. The study population will be compared to a group of age, gender and weight matched normolipidemic controls.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age between 18 and 65 years.
  2. Patients with a metabolic syndrome defined by the presence of >= 3 of the following criteria:

    • Abdominal obesity (waist circumference > 102 cm in men, > 88 cm in women)
    • Fasting plasma triglycerides > 1.7 mmol/l
    • HDL cholesterol < 1.0 mmol/l in men and < 1.3 mmol/l in women
    • Blood pressure > 130/85 mmHg or antihypertensive medication
    • Fasting plasma glucose > 6.1 mmol/l
  3. Patients with Familial Combined Hyperlipidemia characterized by the following criteria:

    • Fasting plasma triglycerides > 1.7 mmol/l
    • Fasting plasma apolipoprotein B concentrations > 1.2 g/l
    • Family history with hypertriglyceridemia and/or hypercholesterolemia present in at least 1 additional first degree family members
  4. Patients with Familial Hypertriglyceridemia characterized by the following criteria:

    • Fasting plasma triglycerides > 2.3 mmol/l
    • Family history of hypertriglyceridemia in at least 1 additional first degree family member
    • Absence of the metabolic syndrome as defined above
  5. Controls fulfilling the following criteria:

    • Non smoking.
    • No current or previous organ or systemic disease (including diabetes and lipid disorders).
    • Plasma triglycerides and cholesterol within the normal range (see exclusion criteria).
    • Plasma glucose concentrations <6.1 mmol/l Subjects meeting criterium 1 and any of the criteria 2. - 5. are eligible for the study.

Exclusion Criteria:

  1. Any significant hepatic, cardiac, pulmonary, renal, neurological, musculoskeletal, hematological or endocrine disease.
  2. Any form of primary or secondary hyperlipidemia other than the metabolic syndrome, FHTG or FCHL. [These may include: Familial hypercholesterolemia and Familial defective apolipoprotein B (to be assessed by family history and lipid profiles), and Familial Dysbetalipoproteinemia (to be assessed by apo E genotyping), hypothyroidism, nephrotic syndrome, diabetes mellitus, cholestatic liver disease, drug induced hyperlipidemia (thiazides > 25 mg/d, non cardioselective betablockers, isotretinoin, systemic glucocorticoids, cyclosporin A, tacrolimus, non nucleoside HIV protease inhibitors)].
  3. Plasma TG levels > 12 mmol/l in the past or at any time point during the study.
  4. History of acute pancreatitis
  5. History of cardiovascular disease, i.e. coronary artery disease, cerebrovascular disease, peripheral vascular disease, when assessed by medical history, physical exam. Additionally, a stress test will be performed in subjects with MS and FCHL at risk for CHD (see below).
  6. Pregnant or Breast Feeding women
  7. Woman of childbearing potential not using a reliable method of birth control such as oral contraceptives or IUD.
  8. Alcohol intake of greater than 1 drink daily.
  9. Cigarette smokers
  10. History of claustrophobia
  11. Ferromagnetic implants including pacemakers.
  12. Subjects refusing or unable to give written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00465751

University Hospital Basel
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Stefan Bilz, MD Cantonal Hospital of St. Gallen
  More Information

Responsible Party: University Hospital, Basel, Switzerland Identifier: NCT00465751     History of Changes
Other Study ID Numbers: EKBB 211/04 SB
Study First Received: April 24, 2007
Last Updated: March 8, 2012

Additional relevant MeSH terms:
Metabolic Syndrome X
Hyperlipoproteinemia Type IV
Hyperlipidemia, Familial Combined
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Chenodeoxycholic Acid
Gastrointestinal Agents processed this record on April 24, 2017